Kidney Cancer: Related News

On Our Blog

Peter Scardino, Chair of MSK’s Department of Surgery and a specialist in the treatment of prostate cancers.
Predicting the Future of Cancer Surgery

Peter Scardino, Chair of MSK’s Department of Surgery, gives his views on what lies ahead for the surgical treatment of cancer.

February 24, 2015
Pictured: William Alago
At Work: Interventional Radiologist William Alago

Interventional radiologist William Alago discusses minimally invasive procedures, advances in imaging techniques, and the future of his field.

November 24, 2014
Pictured: David Solit
At Work: Physician-Scientist David Solit

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.

May 27, 2014
Study Offers Insight into “Obesity Paradox” in Kidney Cancer

Investigators have found a possible molecular explanation for why obese people with kidney cancer tend to fare better despite having a higher rate of diagnosis.

February 6, 2014
Pictured: Robert J. Motzer
Comparison of Drugs for Advanced Kidney Cancer Suggests Side Effects Are More Manageable with Newer Option

An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.

August 22, 2013
Pictured: Pramod Sogani
Pramod Sogani Inaugurated As President of the American Urological Association

Memorial Sloan Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.

July 1, 2013
Pictured: Paul Russo
Many Affected by Kidney Cancer Are Not Informed about Kidney-Sparing Surgery Option

A study has found that the majority of kidney cancer patients with small tumors have their entire kidney removed, which can increase the risk of developing chronic kidney disease and cardiovascular complications.

May 20, 2013
Pictured: Robert Motzer & Suzanne Gornell
Physicians and Scientists at Memorial Sloan Kettering Pioneer the Development of Kidney Cancer Treatments

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

May 8, 2013
Pictured: Guido Dalbagni
Meet Urologic Cancer Surgeon Guido Dalbagni

Dr. Dalbagni – who cares for patients with bladder cancer, kidney cancer, penile cancer, and sarcomas – explains treatments offered at Memorial Sloan Kettering, which can help patients maintain their quality of life.

April 23, 2013
Pictured: Raul Parra
Meet Urologic Cancer Surgeon Raul Parra

Dr. Parra, who practices at Memorial Sloan Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

March 6, 2013
Pictured: David Finley & Maria Teresa Ruiz Tsukazan
Robot-Assisted Surgery at Memorial Sloan Kettering

Our doctors introduce and apply advanced technologies in minimal-access surgery to benefit patients.

February 25, 2013
Pictured: Bernard Bochner
Meet Urologic Surgeon Bernard Bochner

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

January 11, 2013
Pictured: X-ray Image
New Findings Clarify How Kidney Cancer Spreads to Distant Organs

Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.

December 19, 2012
Pictured: Karim Touijer
Meet Urologic Surgeon Karim Touijer

Watch urologic surgeon Karim Touijer discuss our comprehensive approach to cancer care and recent advances in minimally invasive surgery.

July 31, 2012
Pictured: Robert Motzer
New Drug Shows Promise for Patients with Advanced Kidney Cancer

Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.

May 21, 2012
Pictured: Robert Motzer
New Treatment Option for People with Advanced Kidney Cancer

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

February 7, 2012

Related Media Coverage

Kidney Cancer Drugs Equal in Prolonging Survival: Study

Medical oncologist Robert Motzer discussed a study he led that showed that the drug pazopanib works as well as sunitinib for treating advanced kidney cancer.

August 22, 2013